The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States
Abstract
BACKGROUND: Recent studies suggest that thromboprophylaxis is beneficial in preventing venous thromboembolism (VTE) in cancer outpatients, but this is not widely adopted because of incomplete understanding of the contemporary incidence of VTE and concerns about bleeding. Therefore, the authors examined the incidence and predictors of VTE in ambulatory patients with bladder, colorectal, lung, ovary, pancreas, or gastric cancers. METHODS: Data were extracted from a large health care claims database of commercially insured patients in the United States between 2004 and 2009. Demographic and clinical characteristics of the cancer cohort (N = 17,284) and an age/sex‐matched, noncancer control cohort were evaluated. VTE incidence was recorded during a 3‐month to 12‐month follow‐up period after the initiation of chemotherapy. Multivariate analyses were conducted to identify independent predictors of VTE and bleeding. RESULTS: The mean age of the study population was 64 years, and 51% of patients were women. VTE occurred in 12.6% of the cancer cohort (n = 2170) over 12 months after the initiation of chemotherapy versus 1.4% of controls (n = 237; P < .0001); incidence ranged by cancer type from 19.2% (pancreatic cancer) to 8.2% (bladder cancer). Predictors of VTE included type of cancer, comorbidities (Charlson Comorbidity Index score or obesity), and commonly used specific antineoplastic or supportive care agents (cisplatin, bevacizumab, and erythropoietin). CONCLUSIONS: This large, contemporary, real‐world analysis confirmed high rates of VTE in select patients with solid tumors and suggested that the incidence of VTE is high in the real‐world setting. Awareness of the benefits of targeted thromboprophylaxis may result in a clinically significant reduction in the burden of VTE in this population. Cancer 2013. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Self-citationRisk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,171
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 952
Self-citationLevitan, N., Dowlati, A., Remick, S. C., Tahsildar, H. I., Sivinski, L. D., Beyth, R., & Rimm, A. A. (1999) · Medicine · doi:10.1097/00005792-199909000-00001 · Cited by 891
Raffini, L., Huang, Y.-S., Witmer, C., & Feudtner, C. (2009) · Pediatrics · doi:10.1542/peds.2009-0768 · Cited by 825
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., & Lyman, G. H. (2007) · Cancer · doi:10.1002/cncr.23062 · Cited by 781
Self-citationNalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 771
Bennett, C. L. (2008) · JAMA · doi:10.1001/jama.299.8.914 · Cited by 731
Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., Labianca, R., Buzzi, F., Scambia, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70232-3 · Cited by 598
Incidence of Venous Thromboembolism in Patients Hospitalized with Cancer
Stein, P. D., Beemath, A., Meyers, F. A., Skaf, E., Sanchez, J., & Olson, R. E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.06.058 · Cited by 566
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
Gomez, M. L., Gomez‐Raposo, C., & Lobo Samper, F. (2008) · Cancer · doi:10.1002/cncr.23524 · Cited by 549
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj189 · Cited by 548
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
Khorana, A. A., & Connolly, G. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3271 · Cited by 539
Self-citationThromboembolism in Hospitalized Neutropenic Cancer Patients
Khorana, A. A., Francis, C. W., Culakova, E., Fisher, R. I., Kuderer, N. M., & Lyman, G. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8877 · Cited by 475
Self-citationSpencer, F. A., Emery, C., Lessard, D., Anderson, F., Emani, S., Aragam, J., Becker, R. C., & Goldberg, R. J. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00458.x · Cited by 445
Venous Thrombosis in Patients with Solid Tumors: Determination of Frequency and Characteristics
Wan, J., Nguyen, N., & Sallah, S. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613051 · Cited by 411
Epidemiology and pathophysiology of cancer-associated thrombosis
Noble, S., & Pasi, J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605599 · Cited by 396
Cancer and the prothrombotic state
Lip, G. Y., Chin, B. S., & Blann, A. D. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00619-2 · Cited by 378
Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer
Khorana, A. A., Francis, C. W., Blumberg, N., Culakova, E., Refaai, M. A., & Lyman, G. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2377 · Cited by 373
Self-citationSpyropoulos, A. C., & Lin, J. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.6.475 · Cited by 328
Self-citationGemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., Sgouros, J., Gardiner, E., Wedgwood, K., Ettelaie, C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.017 · Cited by 316
Spencer, F. A., Emery, C., Joffe, S. W., Pacifico, L., Lessard, D., Reed, G., Gore, J. M., & Goldberg, R. J. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0378-3 · Cited by 251
Epidemiology of cancer-related venous thromboembolism
Wun, T., & White, R. H. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.12.001 · Cited by 237
The prothrombotic state in cancer: pathogenic mechanisms
De Cicco, M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.10.003 · Cited by 234
Hurwitz, H. I., Saltz, L. B., Van Cutsem, E., Cassidy, J., Wiedemann, J., Sirzén, F., Lyman, G. H., & Rohr, U.-P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3220 · Cited by 226
Prophylaxis for Thromboembolism in Hospitalized Medical Patients
Francis, C. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp067264 · Cited by 195
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3875 · Cited by 194
Lyman, G. H. (2011) · Cancer · doi:10.1002/cncr.25714 · Cited by 190
Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
Hapani, S., Sher, A., Chu, D., & Wu, S. (2010) · Oncology · doi:10.1159/000314980 · Cited by 185
Starling, N., Rao, S., Cunningham, D., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4274 · Cited by 163
Deep vein thrombosis in cancer: the scale of the problem and approaches to management
Falanga, A., & Zacharski, L. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi165 · Cited by 158
Cost of atrial fibrillation in United States managed care organizations
Kim, M. H., Lin, J., Hussein, M. A., Kreilick, C., & Battleman, D. S. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0066-x · Cited by 90
Self-citationGhate, S. R., BISKUPIAK, J. E., Ye, X., Kwong, W. J., & Brixner, D. I. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.9.672 · Cited by 77
Hemostatic complications of angiogenesis inhibitors in cancer patients
Elice, F., Jacoub, J., Rickles, F. R., Falanga, A., & Rodeghiero, F. (2008) · American Journal of Hematology · doi:10.1002/ajh.21277 · Cited by 70
Activation of Clotting Factors in Cancer
Rickles, F. R., & Falanga, A. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-79962-9_3 · Cited by 59
The Link Between Cancer and Venous Thromboembolism: A Review
Kessler, C. M. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181b01b17 · Cited by 55
Kim, M. M., Metlay, J. P., Cohen, A. L., Feldman, H. I., Hennessy, S., Kimmel, S., Strom, B. L., & Doshi, J. A. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1953 · Cited by 41
Happe, L. E., Rao, S. V., Horblyuk, R. V., Franklin, M., Lunacsek, O. E., & Menditto, L. A. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802649133 · Cited by 19
Cited by
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Self-citationLyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Self-citationLyman, G. H., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., Gates, L. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1118 · Cited by 713
Self-citationCancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment
Abdol Razak, N., Jones, G., Bhandari, M., Berndt, M., & Metharom, P. (2018) · Cancers · doi:10.3390/cancers10100380 · Cited by 631
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Ay, C., Pabinger, I., & Cohen, A. T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-08-0615 · Cited by 496
Metadata
- Authors
- Khorana, A. A., Dalal, M., Lin, J., & Connolly, G. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-08-14
- Volume
- 119
- Issue
- 3
- Pages
- 648-655
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1589295587
- Cited by
- 480
- References
- 42
- FWCI
- 16.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.